- Home
- MGTX vs LENZ Comparison
MGTX vs LENZ Comparison
Compare MGTX & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGTX | LENZ |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.9M | 852.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MGTX | LENZ |
|---|---|---|
| Price | $8.57 | $28.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $23.83 | ★ $56.25 |
| AVG Volume (30 Days) | 706.5K | ★ 1.0M |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,417,000.00 | $17,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $619.95 | $204.72 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 96.83 | N/A |
| 52 Week Low | $4.55 | $16.54 |
| 52 Week High | $9.73 | $50.40 |
Technical Indicators
Market Signals| Indicator | MGTX | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 44.78 |
| Support Level | $7.60 | $27.07 |
| Resistance Level | $8.34 | $32.13 |
| Average True Range (ATR) | 0.51 | 2.07 |
| MACD | 0.06 | 0.43 |
| Stochastic Oscillator | 91.81 | 40.39 |
Price Performance
Historical ComparisonAbout MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.